1199 related articles for article (PubMed ID: 33261845)
1. Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review.
Mohamed K; Yazdanpanah N; Saghazadeh A; Rezaei N
Bioorg Chem; 2021 Jan; 106():104490. PubMed ID: 33261845
[TBL] [Abstract][Full Text] [Related]
2. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.
Indu P; Rameshkumar MR; Arunagirinathan N; Al-Dhabi NA; Valan Arasu M; Ignacimuthu S
J Infect Public Health; 2020 Dec; 13(12):1856-1861. PubMed ID: 33168456
[TBL] [Abstract][Full Text] [Related]
3. Computational drug repurposing study of antiviral drugs against main protease, RNA polymerase, and spike proteins of SARS-CoV-2 using molecular docking method.
Jalalvand A; Khatouni SB; Najafi ZB; Fatahinia F; Ismailzadeh N; Farahmand B
J Basic Clin Physiol Pharmacol; 2021 Jul; 33(1):85-95. PubMed ID: 34265888
[TBL] [Abstract][Full Text] [Related]
4. Drug repurposing approach to fight COVID-19.
Singh TU; Parida S; Lingaraju MC; Kesavan M; Kumar D; Singh RK
Pharmacol Rep; 2020 Dec; 72(6):1479-1508. PubMed ID: 32889701
[TBL] [Abstract][Full Text] [Related]
5. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
6. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
[TBL] [Abstract][Full Text] [Related]
7. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
8. Molecular Docking and Virtual Screening Based Prediction of Drugs for COVID-19.
Talluri S
Comb Chem High Throughput Screen; 2021; 24(5):716-728. PubMed ID: 32798373
[TBL] [Abstract][Full Text] [Related]
9. Targeting the coronavirus SARS-CoV-2: computational insights into the mechanism of action of the protease inhibitors lopinavir, ritonavir and nelfinavir.
Bolcato G; Bissaro M; Pavan M; Sturlese M; Moro S
Sci Rep; 2020 Dec; 10(1):20927. PubMed ID: 33262359
[TBL] [Abstract][Full Text] [Related]
10. Drug repurposing for identification of potential inhibitors against SARS-CoV-2 spike receptor-binding domain: An
Behera SK; Mahapatra N; Tripathy CS; Pati S
Indian J Med Res; 2021 Jan & Feb; 153(1 & 2):132-143. PubMed ID: 33818470
[TBL] [Abstract][Full Text] [Related]
11. Repurposing Drugs for COVID-19: An Approach for Treatment in the Pandemic.
Khadka S; Yuchi A; Shrestha DB; Budhathoki P; Al-Subari SMM; Ziad Alhouzani TM; Anwar Butt I
Altern Ther Health Med; 2020 Aug; 26(S2):100-107. PubMed ID: 32827400
[TBL] [Abstract][Full Text] [Related]
12. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
Uzunova K; Filipova E; Pavlova V; Vekov T
Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
[TBL] [Abstract][Full Text] [Related]
13. Drug repurposing for COVID-19 using computational screening: Is Fostamatinib/R406 a potential candidate?
Saha S; Halder AK; Bandyopadhyay SS; Chatterjee P; Nasipuri M; Bose D; Basu S
Methods; 2022 Jul; 203():564-574. PubMed ID: 34455072
[TBL] [Abstract][Full Text] [Related]
14. Repurposing existing drugs for the treatment of COVID-19/SARS-CoV-2 infection: A review describing drug mechanisms of action.
Yousefi H; Mashouri L; Okpechi SC; Alahari N; Alahari SK
Biochem Pharmacol; 2021 Jan; 183():114296. PubMed ID: 33191206
[TBL] [Abstract][Full Text] [Related]
15. Drug repurposing strategies and key challenges for COVID-19 management.
Mule S; Singh A; Greish K; Sahebkar A; Kesharwani P; Shukla R
J Drug Target; 2022 Apr; 30(4):413-429. PubMed ID: 34854327
[TBL] [Abstract][Full Text] [Related]
16. Structural and molecular basis of the interaction mechanism of selected drugs towards multiple targets of SARS-CoV-2 by molecular docking and dynamic simulation studies- deciphering the scope of repurposed drugs.
Skariyachan S; Gopal D; Chakrabarti S; Kempanna P; Uttarkar A; Muddebihalkar AG; Niranjan V
Comput Biol Med; 2020 Nov; 126():104054. PubMed ID: 33074111
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 M
Citarella A; Scala A; Piperno A; Micale N
Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33921886
[TBL] [Abstract][Full Text] [Related]
18. In silico molecular docking analysis for repurposing therapeutics against multiple proteins from SARS-CoV-2.
Deshpande RR; Tiwari AP; Nyayanit N; Modak M
Eur J Pharmacol; 2020 Nov; 886():173430. PubMed ID: 32758569
[TBL] [Abstract][Full Text] [Related]
19. Druggable targets of SARS-CoV-2 and treatment opportunities for COVID-19.
Faheem ; Kumar BK; Sekhar KVGC; Kunjiappan S; Jamalis J; Balaña-Fouce R; Tekwani BL; Sankaranarayanan M
Bioorg Chem; 2020 Nov; 104():104269. PubMed ID: 32947136
[TBL] [Abstract][Full Text] [Related]
20. Understanding the binding mechanism for potential inhibition of SARS-CoV-2 Mpro and exploring the modes of ACE2 inhibition by hydroxychloroquine.
Choudhury M; Dhanabalan AK; Goswami N
J Cell Biochem; 2022 Feb; 123(2):347-358. PubMed ID: 34741481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
